chromatin; HDACi; transcription; acetylation; hdac; small molecules
Abstract :
[en] Histone deacetylase (HDAC) inhibitors are a novel class of promising anti-cancer agents. Little information is available on the capacity of structurally different HDAC inhibitors to induce terminal cell differentiation in different cell types in relation to enzyme inhibition and subtype selectivity. Consequently, the aim of this study was to provide a comprehensive comparison of these effects. New biarylalanine inhibitors of HDAC were synthesized and compared to a series of standard inhibitors from different laboratories. Chromatographically purified rat liver and immunoprecipitated FLAG-tagged recombinant human HDACs were used as sources of HDAC activity. Enzyme inhibition was studied using a fluorescent substrate and its conversion was monitored by high-performance liquid chromatography. The ability to induce cell differentiation was compared in murine (Friend DS-19) and human (K562) erythroleukemic cell lines, and was quantified by benzidine staining. Inhibition of cell proliferation was evaluated by cell counting. All HDAC inhibitors were identified as potent inhibitors of erythroleukemic cell proliferation. However, we observed a complex pattern of differentiation induction: structurally similar inhibitors resulted in disparate activity profiles, whereas similar profiles were detected within distinct structural classes. Among the newly synthesized biarylalanine compounds, a 3'-methoxy derivative was identified as a very effective inducer of terminal cell differentiation. We conclude that investigation of subtype selectivity of selected HDAC inhibitors does not provide a clear link between selectivity and the observed cellular activity profile. The predictive value of in vitro HDAC inhibition assays for identifying anti-proliferative compounds has been emphasized.
Disciplines :
Biochemistry, biophysics & molecular biology Life sciences: Multidisciplinary, general & others
Meinke PT, Liberator P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr Med Chem 2001; 8:211-235.
Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001; 8:1505-1511.
Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998; 10: 373-383.
Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184:1-16.
Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274:34940-34947.
Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94:417-428.
Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000; 6:623-644.
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-299.
Jung M. Histone deacetylases. In: La Thangue NB, Bandara LR (editors): Transcription Factors and Other Nuclear Proteins as Targets for Cancer Chemotherapy. Totowa, NJ: Humana Press; 2002, pp. 123-144.
Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262:75-83.
Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 1995; 17:423-430.
Jung M, Hoffmann K, Brosch G, Loidl P. Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett 1997; 7:1655-1658.
Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhäuser C, et al. Structure-activity relationships on phenylalanine containing inhibitors of histone deacetylase-in-vitro enzyme inhibition, induction of differentiation and inhibition of proliferation in friend leukemic cells. J Med Chem 2002; 45:3296-3309.
Burk MJ, Lee JR, Martinez JRA versatile tandem catalysis procedure for the preparation of novel amino acids and peptides. J Am Chem Soc 1994; 116:10847-10848.
Schmidt K, Gust R, Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch Pharm Pharm Med Chem 1999; 332:353-357.
Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 1999; 42:4669-4679.
Hoffmann K, Brosch G, Loidl P, Jung M. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res 1999; 27:2057-2058.
Hoffmann K, Brosch G, Loidl P, Jung M. First non-radioactive assay for in vitro screening of histone deacetylase inhibitors. Pharmazie 2000; 55: 601-606.
Heltweg B, Jung M. A micro plate reader based non-isotopic histone deacetylase activity assay. Anal Biochem 2002; 302:175-183.
Hoffmann K, Heltweg B, Jung M. Improvement and validation of the fluorescence-based histone deacetylase assay using an internal standard. Arch Pharm Pharm Med Chem 2001; 334:248-252.
Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W, et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem 1999; 274:11713-11720.
Richon VM, Rifkind RA, Marks PA. Differentiation of murine erythroleukemia cells (Friend leukemia cells). In: Cell Biology: A Laboratory Handbook. New York: Academic Press; 1994, pp. 213-217.
Kolle D, Brosch G, Lechner T, Lusser A, Loidl P. Biochemical methods for analysis of histone deacetylases. Methods 1998; 15:323-331.
Topliss JG. A manual method for applying the Hansch approach to drug design. J Med Chem 1977; 20:463-469.
Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265:17174-17179.
Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 2000; 60:3137-3142.
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007.
Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96:4592-4597.
Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42:3001-3003.
Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, et al. Subtype selective substrates for histone deacetylases. J Med Chem 2004; 47:5235-5243.
Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2003; 2:401-408.
Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 1987; 47:3688-3691.
Lea MA, Randolph VM, Hodge SK. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 1999; 19:1971-1976.
Marks PA, Richon VM, Kiyokawa H, Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci USA 1994; 91:10251-10254.
Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004; 10:5271-5281.
Remiszewski SW, Sambuccetti LC, Atadja P, Bair KW, Cornell WD, Green MA, et al. Inhibitors of human histone deacetylase: synthesis, enzyme and cellular activity of straight chain hydroxamates. J Med Chem 2002; 45: 753-757.
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401:188-193.
Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004; 12:1325-1334.
Heltweg B, Jung M. A homogeneous non-isotopic assay for histone deacetylase activity. J Biomol Screen 2003; 8:89-95.
Wegener D, Wirsching F, Riester D, Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 2003; 10:61-68.
Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 2004; 103:701-709.
Zhang Y, Jung M, Dritschilo A, Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004; 161:667-674.
Emiliani S, Fischle W, Van Lint C, Al Abed Y, Verdin E. Characterization of a human rpd3 ortholog, HDAC3. Proc Natl Acad Sci USA 1998; 95: 2795-2800.
Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001; 98:87-92.
